Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
about
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyDevelopment of Liposomal Ciprofloxacin to Treat Lung InfectionsGatifloxacin, an advanced 8-methoxy fluoroquinolone.Do we need an intravenous fluoroquinolone?Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patientsPopulation pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosisCiprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infectionDetermination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infectionIn vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.What do we really know about antibiotic pharmacodynamics?Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin.Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosaPharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsisDevelopment of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similarMicrobiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscessesEvaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targetsDouble-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.Modeling the response of pneumonia to antimicrobial therapy.Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
P2860
Q24519008-D85C63CC-98BF-4039-98CF-5FC55EDFDB96Q26764772-861C2BE0-A220-4542-BC4D-A20D8D69D6CEQ31975922-812B6894-563A-4D55-BCF2-896945BC9DA0Q33606570-B0C7623F-2FD1-4253-B38B-978CE69BAF33Q33751215-13192440-E8CC-4A01-8144-8332A5122B92Q33753240-436C8507-9B23-41CA-926B-5A7CE04843E9Q33876615-1AE19229-B3A4-4BB0-A215-6CA5B470B131Q33982098-ECB9BA6A-BF8B-4231-818D-8C9114746393Q33983228-CDA50DD0-313D-4372-86A7-9ABEE88A55AEQ33983611-7AB595B0-B296-4B06-8BDF-11FBDF0652E6Q34110906-921FF70A-7AC7-4D4C-A9E8-CE350854B2B7Q34141627-5F236EF2-333C-4EC2-A125-562A2C11C494Q34251731-CC5FA2A6-779C-4464-94F3-29E8054D5EEDQ34274190-744BFD25-9994-4F36-824B-540E9751853CQ34443407-E3A94AF9-0332-4305-8CDC-EB4222D34650Q34736543-B2EA4426-79FE-4CD5-ABCA-1F3341C84A2EQ35140423-55735A08-A5EB-4F70-9F5A-D7B6DE4D180CQ35168927-9B34CA6F-BD45-4FAA-8957-C5B40927971FQ35533543-E1DE3FC9-2D83-443D-8DA7-54688862DFACQ35666434-4EF68803-0084-4E52-B263-244DED8F0C4EQ35810298-6FA6101F-DBBE-4198-9C77-56F0B8FCF1F4Q35814771-8C25D9E7-67C6-4569-B99D-609F083EAF7FQ35814807-C258FD90-B5A9-4F52-A9B0-EC7BF4C4C926Q35818681-3217DEBC-BE69-4241-A34E-00363AB929E8Q35822946-E4415636-BC51-4813-97FC-0830680015A6Q35941373-8C85C2CB-475B-41D3-9EAF-FD53F0C4ADE2Q36644902-2A172FF2-92E0-4B7D-8650-416EEDEC394EQ36863646-67BB14A2-BC39-4696-9EF8-478A309F44E2Q37204214-E12F0CE5-FB67-47A8-B1C1-CED10ABACA53Q37274632-44A63B72-962F-457F-9181-8D70048F2550Q39557455-90EA26C6-6102-4A45-A2A2-8EBD2E5BCF3EQ39781591-3B5AAA8B-C0D1-4505-A03C-F3CB9FE59142Q39784308-DD9A0E8D-EA20-4228-988E-03EA0F1B5749Q40285699-E71D189E-9F39-40B5-B154-8BDAE646D79EQ42686155-38BCAE07-0EB0-451A-8993-DA4EFD5FB478
P2860
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Evaluation of intravenous cipr ...... tion on bacterial eradication.
@en
Evaluation of intravenous cipr ...... tion on bacterial eradication.
@nl
type
label
Evaluation of intravenous cipr ...... tion on bacterial eradication.
@en
Evaluation of intravenous cipr ...... tion on bacterial eradication.
@nl
prefLabel
Evaluation of intravenous cipr ...... tion on bacterial eradication.
@en
Evaluation of intravenous cipr ...... tion on bacterial eradication.
@nl
P2093
P1476
Evaluation of intravenous cipr ...... tion on bacterial eradication.
@en
P2093
P304
P356
10.1001/ARCHINTE.149.10.2269
P407
P577
1989-10-01T00:00:00Z